Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:08 PM
Ignite Modification Date:
2025-12-24 @ 4:08 PM
NCT ID:
NCT05552066
Eligibility Criteria:
Inclusion Criteria:
* Age greater than 18 years
* Patient treated for solid malignancy
* Patient starting a new chemotherapy or immunotherapy protocol.
* Patient receiving one of the following intravenous antineoplastic treatments in day hospital: Nivolumab(1), Pembrolizumab(1), Folfox(2), Folfirinox(2), Xelox Carboplatin, EC chemotherapy (Epirubicin/Cyclophosphamide)
* Affiliated and beneficiary to a social security system
* Informed and written consent
Note1: may be used in combination with tyrosine kinase inhibitors (TKIs) Note 2 :may be used in combination with bevacizumab, cetuximab or panitumumab
Exclusion Criteria:
* Patient treated in neo-adjuvant situation for breast cancer
* Does not have a connected device (smartphone, tablet or computer)
* Does not have an internet connection
* Difficulty in filling out a questionnaire
* Protected adult or deprived of her liberty
* Pregnant or lactating woman
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05552066
Study Brief:
Protocol Section:
NCT05552066